Letters, Testimony & Comments

On behalf of the 23 undersigned industrial, environmental, food and agricultural biotechnology companies, we write to express our...
June 12 2012
If a poor patient in Nevada doesn’t have access to an advanced molecular diagnostic test, and right across the border in California...
February 17 2012
BIO has identified the following countries of interest and recommends the following for our 2011 Special 301 submission. Priority...
February 14 2012
Patent Amendment (Human Genes and Biological Materials) Bill 2010 Submission to the Senate Legal and Constitutional Affairs Legislation...
February 25 2011
Recommendations in the Secretary’s Advisory Committee on Genetics, Health and Society draft report on Gene Patenting and Licensing...
October 8 2009
Dear Secretary Vilsack: We are writing today to bring to your attention a court case that has the potential to negatively impact the...
September 9 2009
The Comments of the Biotechnology Industry Organization on the United States Patent & Trademark Office Proposed Rule Changes...
October 30 2007
The Honorable Michael Harris, M.P.P. Premier of Ontario Legislative Assembly of Ontario Room 281 Legislative Building Toronto,...
September 26 2001
WASHINGTON, D.C. (July 13, 2000) -- Executives from two Biotechnology Industry Organization (BIO) member companies testified today...
July 13 2000
February 1 2013
BIO commends the INPI for their efforts to devise guidelines for examining biotechnology related inventions. Given the technological advances and the innovation that spurs it are the primary drivers of economic growth in the modern era, it is critical that patent laws and practices properly motivate and reward innovation.
February 14 2012
BIO has identified the following countries of interest and recommends the following for our 2011 Special 301 submission.
February 25 2011
BIO believes that the proposed amendment would, if adopted, have significant unintended and adverse consequences in all sectors of biotechnology and for patients and consumers in Australia. This amendment also would fail to affect its intended purpose, which is to advance medical and scientific research and the diagnosis and cure of human illness and disease.
June 13 2013
The SCOTUS decision represents a departure from judicial and PTO precedent supporting patentability of DNA molecules. The decision could create business uncertainty for a range of inventions.